The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
PPMI Sample Request, 2014Whole Blood RNA Biomarkers of Parkinson’s Disease
Objective/Rationale:
When a Parkinson’s disease patient first experiences motor symptoms, most of the neurons in the part of the brain affected by the disease have already died and therefore the... -
Resource: Utilizing DATATOP Biospecimens, 2011Validation of Alpha-synuclein Oligomers as Biomarker for Parkinson’s Disease
Objective/Rationale:
We have reported recently higher levels of α-synuclein oligomers species in cerebral spinal fluid (CSF) from patients clinically diagnosed with Parkinson’s disease (PD) versus... -
Rapid Response Innovation Awards, 2007Methylphenidate for the Treatment of Gait Impairment in Parkinson's Disease
Objective/Rationale:
The objective of this study is to explore the effects of methylphenidate on the gait of patients with Parkinson’s disease who are experiencing shuffling and freezing... -
Clinical Intervention Awards, 2007The PARKFIT Study: Effectiveness of an Active Lifestyle Promotion Program for Patients with Parkinson’s disease
Objective/Rationale:
Parkinson's patients are inclined toward a sedentary lifestyle. This is due to a combination of both physical handicaps (e.g. walking difficulties) and mential impairments (e.g... -
Research Grant, 2010Longitudinal Follow-Up of Clinical and Neuroimaging Signs and Biomarkers in Symptoms & Side Effects and aSymptoms & Side Effects LRRK2 Mutation Carriers in Comparison to Idiopathic PD and Controls
Objective/Rationale:
Parkinson’s disease (PD) is a common neurodegenerative disease that leads to progressive motor impairment as well as autonomic and cognitive disturbances. The cause of most of... -
Rapid Response Innovation Awards, 2013Topography of Vulnerability to Alpha-synuclein Fibrils in the Cerebral Cortex
Objective/Rationale:
In Parkinson’s disease, the neocortex (outer layer of the brain’s cerebral hemispheres, made of six layers) is less vulnerable than the allocortex (fewer than six...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.